NeuroMetrix Announces Availability of Quell Wearable Pain Relief Technology at Best Buy
February 21 2017 - 11:00AM
Business Wire
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell®
will be available in over 450 Best Buy® stores nationwide beginning
in mid-February and is now available for purchase on
BestBuy.com.
"More and more consumers are proactively looking for technology
to help manage their health," said Frank McGillin, Senior Vice
President and Chief Commercial Officer at NeuroMetrix, "We are
excited that Quell consumers will be able to experience the
expertise and service that Best Buy is known for.”
About Quell
Quell is designed for millions of people suffering from chronic
pain. The advanced wearable device is lightweight and can be worn
during the day while active, and at night while sleeping. It has
been cleared by the FDA for treatment of chronic pain without a
prescription. In a recent study, 81% of Quell users reported an
improvement in their chronic pain. Quell users can personalize and
manage therapy discreetly via the Quell Relief app. Quell also
offers advanced health tracking relevant to chronic pain sufferers
including pain, sleep, activity, and gait. Quell was the winner of
the 2016 SXSW (South by Southwest) Innovation Award for Best
Wearable Technology. Quell is available at select healthcare
professionals and retailers. Visit QuellRelief.com for more
information.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare
company combining bioelectrical and digital medicine to address
chronic health conditions including chronic pain, sleep disorders,
and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain.
Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic
pain on their quality of life. The company also markets DPNCheck®,
a rapid point-of-care test for diabetic neuropathy, which is the
most common long-term complication of Type 2 diabetes. The company
maintains an active research effort and has several pipeline
programs, including a therapeutic device for restless leg syndrome.
The company is located in Waltham, Massachusetts and was founded as
a spinoff from the Harvard-MIT Division of Health Sciences and
Technology in 1996. For more information, please visit
Neurometrix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170221005336/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Sep 2023 to Sep 2024